Denali Therapeutics Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Denali Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $0.00.
- Denali Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $12.37M.
- Denali Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- Denali Therapeutics Inc. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00.
- Denali Therapeutics Inc. stock issued during period, value, new issues for fiscal 2025 was $189.25M, a 62.09% decline from fiscal 2024.
- Denali Therapeutics Inc. stock issued during period, value, new issues for fiscal 2024 was $499.25M.
- Denali Therapeutics Inc. stock issued during period, value, new issues for fiscal 2022 was $296.21M.
- Denali Therapeutics Inc. stock issued during period, value, new issues for fiscal 2020 was $193.95M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | |
| 2026-03-31 | $12.37M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $189.25M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $499.25M 10-K · filed 2026-02-26 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | |
| 2024-03-31 | $499.25M 10-Q · filed 2025-05-06 | |
| 2022-12-31 | $296.21M 10-K · filed 2025-02-27 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $193.95M 10-K · filed 2023-02-27 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | |
| 2020-03-31 | $193.95M 10-Q · filed 2021-05-05 | |
| 2017-12-31 | $264.26M 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |